To overcome these limitations, several strategies to reduce systemic toxicity and implement the anti-tumor efficacy of TNFα have been investigated, including local administration [122] and specific delivery via nanoparticles [123,124] or targeting antibodies/peptides [125,126]. Here, TNF is linked to neoplasm.